Are you ready for the new reality?
Precision Medicine Group is the first scientific services company fully equipped to accelerate biomarker-informed drug development and drive commercial success.
Biotech innovators need more than benchtop acumen. They need an integrated model capable of harnessing clinical and biological data and analyzing this information to extract critical insights.
Precision Medicine Group is the only molecule-to-market scientific services company built to accelerate today’s development process.
A breakthrough isn’t defined by its approval; it’s defined by its ability to change behaviors and improve results. That can only happen when the value of this breakthrough is expressed in a way that resonates to all constituencies, from physician to patient to payer.
The expertise of Precision Medicine Group goes beyond drug development. Our commercialization capabilities are focused on ensuring that medical innovations are recognized, valued, and accessible to patients.
Ready to develop
So are we.
NEXT-GEN CLINICAL DEVELOPMENT
The drug and diagnostic development businesses of Precision Medicine Group, collectively known as Precision for Medicine, are industry leaders in the design, development, and execution of biomarker-informed clinical studies and complex data management. Our best-in-class CRO services ensure clients accelerate time to market while reducing costs and minimizing risk.
The commercially focused businesses of Precision Medicine Group, known as Precision Value & Health, specialize in researching and creating communications for investors, payers, HCPs, consumers, and the scientific community at large. We leverage our extensive experience to develop impactful brand stories that influence key stakeholders.
News & Updates
May 11, 2020
Mark Clein, Co-Founder and CEO of Precision Medicine Group, delivers the keynote address for BioTrin...
April 21, 2020
Precision for Medicine Partners with Karyopharm Therapeutics to Initiate New Global Clinical Trial t...
April 7, 2020
Precision Value & Health Shifts the Trajectory with Convergence of Brands under One Umbrella